Generate 150 high yeild mcqs for sple doctor of pharmacy i regarding cardiology drugs , disease, contraindications, adrs, in detail

Reading File

Finding Sources

I now have sufficient library data combined with my extensive pharmacology knowledge to generate all 150 high-yield MCQs. Let me compile them now.

150 High-Yield MCQs - SPLE Doctor of Pharmacy I: Cardiology

Topics covered: Antihypertensives, Heart Failure, Antiarrhythmics, Anticoagulants, Lipid-Lowering Agents, Antianginals, Cardiac Glycosides, Thrombolytics, Antiplatelet Agents, Acute Coronary Syndromes, Cardiomyopathy, Dyslipidemia, Arrhythmias, ADRs, Contraindications, Drug Interactions

SECTION 1: BETA-BLOCKERS (Q1-15)

Q1. A patient with hypertension and asthma is prescribed metoprolol. Which concern is most relevant?

A) Hypoglycemia masking
B) Bronchospasm
C) Reflex tachycardia
D) Hyperkalemia

Answer: B - Beta-blockers (especially non-selective like propranolol) cause bronchospasm via beta-2 blockade. Even cardioselective beta-1 blockers like metoprolol carry risk in asthma. Asthma is a contraindication to beta-blockers.

Q2. Which beta-blocker has intrinsic sympathomimetic activity (ISA) and is less likely to cause resting bradycardia?

A) Atenolol
B) Pindolol
C) Metoprolol
D) Bisoprolol

Answer: B - Pindolol has ISA (partial agonist activity) at beta receptors, so it partially activates them at rest, reducing bradycardia while still blocking excess sympathetic activity.

Q3. A diabetic patient on insulin develops hypoglycemia. The nurse notes that the usual warning signs (tremor, tachycardia) are absent. Which antihypertensive is most likely responsible?

A) Amlodipine
B) Lisinopril
C) Propranolol
D) Hydrochlorothiazide

Answer: C - Non-selective beta-blockers like propranolol mask the adrenergic symptoms of hypoglycemia (tachycardia, tremor) by blocking beta-2 receptors, while sweating (cholinergic) is preserved.

Q4. Carvedilol differs from metoprolol in having additional:

A) Beta-2 agonist activity
B) Alpha-1 blocking activity
C) Calcium channel blocking activity
D) ACE inhibiting activity

Answer: B - Carvedilol is a non-selective beta-blocker with additional alpha-1 blocking activity, providing vasodilation. It is used in heart failure and hypertension.

Q5. A patient on propranolol suddenly stops the medication. Which condition is most likely to occur?

A) Hypertensive urgency
B) Rebound hypertension and angina
C) First-dose hypotension
D) Reflex bradycardia

Answer: B - Abrupt withdrawal of beta-blockers can cause rebound hypertension, angina, and even myocardial infarction due to upregulation of beta receptors during therapy. Always taper.

Q6. Beta-blockers are the drug of choice for all of the following EXCEPT:

A) Post-MI with reduced EF
B) Hypertension in a patient with Raynaud's phenomenon
C) Rate control in atrial fibrillation
D) Stable angina

Answer: B - Raynaud's phenomenon is a contraindication to beta-blockers (especially non-selective) because blocking beta-2 vasodilation in periphery worsens vasospasm.

Q7. Which beta-blocker is preferred in patients with heart failure with reduced ejection fraction (HFrEF)?

A) Atenolol
B) Metoprolol succinate
C) Propranolol
D) Acebutolol

Answer: B - Evidence-based beta-blockers for HFrEF are carvedilol, metoprolol succinate (CR/XL), and bisoprolol. Atenolol and propranolol do not have mortality benefit in HF.

Q8. A patient presents with bradycardia, hypotension, and bronchospasm after an overdose. Which antidote is most appropriate?

A) Atropine
B) Glucagon
C) Naloxone
D) Phentolamine

Answer: B - Glucagon activates adenylyl cyclase independently of beta receptors, bypassing the blockade. It is the antidote of choice for beta-blocker overdose. Atropine can treat bradycardia but does not reverse all effects.

Q9. Which of the following is TRUE regarding labetalol?

A) It is a selective beta-1 blocker
B) It blocks alpha-1 and beta receptors
C) It is first-line in acute asthma
D) It causes reflex tachycardia

Answer: B - Labetalol blocks both alpha-1 and non-selective beta receptors (1:7 alpha:beta ratio IV; 1:3 oral). Used in hypertensive emergencies in pregnancy (eclampsia).

Q10. The mechanism of beta-blocker action in angina includes:

A) Coronary vasodilation
B) Reduction of heart rate and contractility (decreased O2 demand)
C) Inhibition of platelet aggregation
D) Blocking calcium channels

Answer: B - Beta-blockers reduce heart rate, contractility, and systolic wall stress, thereby decreasing myocardial oxygen demand. This is the primary anti-anginal mechanism.

Q11. Bisoprolol has a beta-1 selectivity ratio of approximately:

A) 1:1
B) 10:1
C) 75:1
D) 1000:1

Answer: C - Bisoprolol has very high beta-1 selectivity (~75:1), making it one of the most cardioselective beta-blockers available, suitable for patients with mild-moderate asthma or COPD with careful monitoring.

Q12. A patient on a beta-blocker develops cold extremities, fatigue, and sexual dysfunction. These are classified as:

A) Idiosyncratic reactions
B) Dose-independent type B reactions
C) Pharmacological (type A) adverse drug reactions
D) Hypersensitivity reactions

Answer: C - Cold extremities (peripheral vasoconstriction), fatigue, and sexual dysfunction are predictable, dose-dependent, pharmacological (type A) ADRs related to beta blockade.

Q13. Which beta-blocker is used topically for glaucoma?

A) Carvedilol
B) Timolol
C) Nebivolol
D) Atenolol

Answer: B - Timolol eye drops reduce intraocular pressure by decreasing aqueous humor production. Systemic absorption can cause bradycardia and bronchospasm.

Q14. Nebivolol's unique property among beta-blockers is:

A) Alpha-1 blockade
B) Nitric oxide-mediated vasodilation
C) ISA activity
D) Calcium channel blockade

Answer: B - Nebivolol stimulates endothelial beta-3 receptors and induces NO-mediated vasodilation. This gives it additional antihypertensive effects beyond beta-1 blockade.

Q15. A patient with heart block (2nd degree Mobitz II) is started on a new drug for chest pain and develops complete heart block. Which drug caused this?

A) Amlodipine
B) Isosorbide mononitrate
C) Verapamil
D) Nitroglycerin

Answer: C - Verapamil (and diltiazem) are contraindicated in advanced heart block because they slow AV nodal conduction. They can precipitate complete heart block.

SECTION 2: CALCIUM CHANNEL BLOCKERS (Q16-25)

Q16. Which calcium channel blocker is preferred in hypertension with concurrent Prinzmetal's (vasospastic) angina?

A) Atenolol
B) Nifedipine
C) Verapamil
D) Either B or C

Answer: D - Both dihydropyridines (nifedipine) and non-dihydropyridines (verapamil, diltiazem) relieve coronary vasospasm. Beta-blockers are contraindicated in Prinzmetal's angina as they can worsen vasospasm.

Q17. A patient on amlodipine develops pedal edema. This is caused by:

A) Sodium and water retention via kidneys
B) Precapillary vasodilation without matched venous dilation, increasing capillary pressure
C) Aldosterone release
D) Direct renal toxicity

Answer: B - Dihydropyridine CCBs (amlodipine, nifedipine) preferentially dilate arterioles. The increased hydrostatic pressure causes fluid shift into interstitium, causing peripheral edema.

Q18. The drug of choice for rate control in atrial fibrillation in a patient who cannot tolerate beta-blockers is:

A) Amlodipine
B) Diltiazem or verapamil
C) Nifedipine
D) Nimodipine

Answer: B - Non-dihydropyridines (diltiazem, verapamil) slow AV nodal conduction and control ventricular rate in AF. Dihydropyridines (amlodipine, nifedipine) have no AV nodal effects.

Q19. Nimodipine is specifically used for:

A) Supraventricular tachycardia
B) Cerebral vasospasm after subarachnoid hemorrhage
C) Hypertensive emergency
D) Prinzmetal's angina

Answer: B - Nimodipine is highly lipophilic and penetrates the CNS well. It preferentially dilates cerebral arteries and is used to prevent/treat cerebral vasospasm after subarachnoid hemorrhage.

Q20. Verapamil is contraindicated with which drug combination?

A) ACE inhibitors
B) Statins
C) IV beta-blockers (e.g., IV propranolol)
D) Aspirin

Answer: C - Combining IV verapamil with IV beta-blockers can cause severe bradycardia, heart block, and asystole. Both slow AV node conduction and have negative inotropic effects.

Q21. Which CCB is the drug of choice for hypertensive crisis with acute aortic dissection (after beta-blocker)?

A) Nifedipine oral
B) Nicardipine IV
C) Verapamil oral
D) Amlodipine oral

Answer: B - IV nicardipine (or clevidipine) provides titratable BP reduction. Oral nifedipine is now avoided in hypertensive emergencies due to unpredictable, rapid BP drops.

Q22. Amlodipine's long half-life (~35-50 hours) is clinically important because:

A) It requires renal dose adjustment
B) A missed dose does not cause rebound hypertension
C) It requires twice-daily dosing
D) It has faster onset than other CCBs

Answer: B - Amlodipine's long half-life allows once-daily dosing and provides smooth, sustained BP control without rebound effects if a dose is missed.

Q23. Verapamil inhibits which drug transporter, increasing levels of co-administered drugs?

A) OAT1
B) P-glycoprotein (P-gp)
C) OCT2
D) BCRP

Answer: B - Verapamil inhibits P-glycoprotein and CYP3A4. This increases digoxin levels by 50-90% and increases levels of cyclosporine, statins, and other CYP3A4 substrates.

Q24. A patient on verapamil for AF develops constipation. This is because:

A) Autonomic neuropathy
B) Calcium channel blockade in smooth muscle of GI tract
C) Anticholinergic effect
D) Alpha-1 blockade

Answer: B - Verapamil blocks calcium channels in GI smooth muscle, reducing peristalsis and causing constipation. This is the most common GI side effect.

Q25. Clevidipine is different from other IV CCBs in that it:

A) Has a half-life of 24 hours
B) Is metabolized by plasma esterases (ultra-short acting, t1/2 ~1 min)
C) Has AV nodal blocking effects
D) Causes reflex bradycardia less than other drugs

Answer: B - Clevidipine is an ultra-short-acting IV dihydropyridine hydrolyzed by plasma esterases. Its very short half-life (~1 min) allows precise BP titration in perioperative hypertension.

SECTION 3: ACE INHIBITORS & ARBs (Q26-38)

Q26. A patient on lisinopril develops a non-productive cough after 3 weeks. The cough is caused by:

A) Bradykinin accumulation in the lungs
B) Angiotensin II excess
C) Aldosterone escape
D) Direct lung toxicity

Answer: A - ACE normally degrades bradykinin. ACE inhibitors prevent bradykinin breakdown, causing accumulation in the lungs, stimulating sensory fibers and causing a dry cough (incidence ~10-15%).

Q27. The most dangerous adverse effect of ACE inhibitors is:

A) Hyperkalemia
B) Angioedema
C) Hypotension
D) Renal insufficiency

Answer: B - Angioedema (swelling of tongue, lips, throat) is life-threatening and occurs in ~0.1-0.5% of patients. It is caused by bradykinin accumulation and can cause airway obstruction. It is a reason to permanently discontinue ACE inhibitors.

Q28. ACE inhibitors are contraindicated in all of the following EXCEPT:

A) Bilateral renal artery stenosis
B) Pregnancy
C) Hyperkalemia (K+ > 5.5 mEq/L)
D) Type 2 diabetes with microalbuminuria

Answer: D - ACE inhibitors are actually INDICATED in diabetic nephropathy (type 2 diabetes with microalbuminuria) as they are renoprotective. They reduce glomerular hypertension by dilating the efferent arteriole.

Q29. A patient with bilateral renal artery stenosis is started on an ACE inhibitor. Acute kidney injury occurs because:

A) Direct nephrotoxicity of ACE inhibitors
B) Efferent arteriole dilation drops GFR in already-compromised kidneys
C) Afferent arteriole constriction
D) Increased renin release damages kidneys

Answer: B - In renal artery stenosis, GFR is maintained by angiotensin II-mediated efferent arteriole constriction. ACE inhibitors abolish this compensatory mechanism, causing GFR to drop precipitously.

Q30. The preferred drug in a patient who developed ACE inhibitor-induced cough and needs RAAS blockade is:

A) Beta-blocker
B) Angiotensin receptor blocker (ARB)
C) Aldosterone antagonist
D) Direct renin inhibitor

Answer: B - ARBs (losartan, valsartan, etc.) block AT1 receptors but do NOT inhibit ACE, so bradykinin is degraded normally and cough does not occur. They are used when ACE inhibitors are not tolerated.

Q31. Losartan has a unique property among ARBs in that it:

A) Increases uric acid levels
B) Lowers uric acid levels (uricosuric effect)
C) Has dual ACE and ARB activity
D) Is metabolized to an inactive metabolite

Answer: B - Losartan has a mild uricosuric effect, making it the preferred ARB in hypertensive patients with gout.

Q32. Combining an ACE inhibitor with an ARB (dual RAAS blockade) is:

A) Recommended for all heart failure patients
B) Standard of care in diabetic nephropathy
C) Generally not recommended due to increased risk of renal failure, hypotension, and hyperkalemia
D) Beneficial in reducing mortality in all hypertensive patients

Answer: C - The ONTARGET trial showed that dual RAAS blockade increases adverse events (renal failure, hypotension, hyperkalemia) without additional benefit. It is generally contraindicated except in select HF patients.

Q33. Sacubitril/valsartan (Entresto) works by:

A) Blocking AT1 receptors and inhibiting ACE
B) Blocking AT1 receptors and inhibiting neprilysin (which degrades natriuretic peptides)
C) Blocking beta receptors and AT1 receptors
D) Blocking ACE and neprilysin

Answer: B - Sacubitril is a neprilysin inhibitor (prodrug). Neprilysin degrades natriuretic peptides. Blocking neprilysin increases BNP/ANP, causing vasodilation and diuresis. Combined with valsartan (ARB). Sacubitril/valsartan is contraindicated with ACE inhibitors (angioedema risk).

Q34. A pregnant woman in the first trimester has been taking enalapril. What is the most serious fetal risk?

A) Neural tube defects
B) Fetal renal dysgenesis, oligohydramnios, limb contractures, skull hypoplasia
C) Cardiac malformations
D) Pulmonary hypoplasia only

Answer: B - ACE inhibitors in the 2nd and 3rd trimester cause fetal ACE inhibitor fetopathy: renal tubular dysgenesis, oligohydramnios (from decreased fetal urine output), limb contractures, skull hypoplasia, and death. They are Category D/X in pregnancy.

Q35. Captopril differs from enalapril in that captopril:

A) Has a longer half-life
B) Contains a sulfhydryl (SH) group and is active as the parent drug
C) Has no food interactions
D) Is a prodrug

Answer: B - Captopril has an active sulfhydryl group (SH) and is active as given. Enalapril is a prodrug (enalaprilat is the active form). Captopril requires twice or three-times daily dosing and must be taken on an empty stomach. The SH group may contribute to taste disturbance and rash.

Q36. Which ACE inhibitor does NOT require renal dose adjustment?

A) Enalapril
B) Lisinopril
C) Fosinopril
D) Ramipril

Answer: C - Fosinopril has dual elimination (hepatic + renal), so it does not require dose adjustment in renal impairment. Most ACE inhibitors are renally eliminated and need dose reduction in CKD.

Q37. The mechanism by which ACE inhibitors are renoprotective in diabetic nephropathy:

A) Increase GFR by dilating afferent arteriole
B) Reduce intraglomerular pressure by dilating efferent arteriole
C) Block aldosterone and reduce tubular damage
D) Direct antifibrotic effect on mesangium

Answer: B - ACE inhibitors reduce angiotensin II, dilating the efferent arteriole more than the afferent. This reduces intraglomerular pressure and proteinuria, slowing progression of diabetic nephropathy.

Q38. Aliskiren (direct renin inhibitor) is contraindicated with ACE inhibitors/ARBs especially in:

A) Heart failure with reduced EF
B) Patients with diabetes or renal impairment
C) Patients with hypertension only
D) Elderly patients

Answer: B - The FDA contraindicated combining aliskiren with ACE inhibitors or ARBs in patients with diabetes or GFR < 60, due to risk of renal failure, hypotension, and hyperkalemia (ALTITUDE trial).

SECTION 4: DIURETICS IN CARDIOLOGY (Q39-48)

Q39. Furosemide's mechanism of action is:

A) Inhibition of Na-K-Cl cotransporter in the thick ascending limb of Henle
B) Inhibition of Na-Cl cotransporter in distal convoluted tubule
C) Aldosterone receptor blockade in collecting duct
D) Carbonic anhydrase inhibition in proximal tubule

Answer: A - Furosemide (loop diuretic) blocks the Na-K-2Cl cotransporter (NKCC2) in the thick ascending limb, producing powerful diuresis. This also increases Ca2+ and Mg2+ excretion.

Q40. A patient on long-term furosemide develops muscle weakness, EKG changes (U waves, flattened T waves). The most likely cause is:

A) Hyperkalemia
B) Hypokalemia
C) Hypercalcemia
D) Hypomagnesemia

Answer: B - Loop diuretics cause hypokalemia. EKG signs of hypokalemia include flattened/inverted T waves and U waves. Severe hypokalemia can cause arrhythmias.

Q41. Spironolactone causes gynecomastia and sexual dysfunction in men because it:

A) Inhibits testosterone synthesis
B) Blocks androgen receptors (anti-androgenic effect)
C) Increases estrogen levels
D) Causes prolactin release

Answer: B - Spironolactone is a non-selective mineralocorticoid antagonist that also blocks androgen receptors, causing gynecomastia, impotence, and menstrual irregularities. Eplerenone is more selective and has fewer hormonal effects.

Q42. The mortality benefit of spironolactone in heart failure (RALES trial) is in patients with:

A) Any degree of heart failure
B) HFrEF with NYHA Class III-IV already on ACE inhibitor and loop diuretic
C) HFpEF with preserved EF
D) Hypertensive heart disease only

Answer: B - The RALES trial showed spironolactone (25-50 mg/day) reduces mortality by 30% in patients with severe HFrEF (EF <35%, NYHA III-IV) already on standard therapy.

Q43. Hydrochlorothiazide is contraindicated or used with caution in patients with:

A) Hypertension with metabolic syndrome
B) Gout
C) Hypertension alone
D) Osteoporosis

Answer: B - Thiazides reduce uric acid excretion and raise serum uric acid levels, precipitating gout attacks. They also cause hyperglycemia, hyperlipidemia, hypokalemia, and hyponatremia.

Q44. The "J-curve" hypothesis in antihypertensive therapy refers to:

A) Increased risk of stroke at very high BP
B) Increased risk of coronary events when diastolic BP is lowered too much (below ~70 mmHg)
C) U-shaped mortality curve with beta-blockers
D) Risk of HF with low sodium diets

Answer: B - The J-curve hypothesis suggests that excessively lowering diastolic BP (below ~70 mmHg) may increase coronary events because coronary perfusion occurs during diastole.

Q45. Torsemide differs from furosemide in having:

A) Shorter half-life
B) Longer duration of action and more predictable oral bioavailability
C) A different mechanism (NCC inhibition)
D) Weaker diuretic effect

Answer: B - Torsemide has better oral bioavailability (~80% vs ~50% for furosemide) and longer duration of action. The TRANSFORM-HF trial compared furosemide vs torsemide in HF.

Q46. Amiloride's mechanism differs from spironolactone in that amiloride:

A) Blocks aldosterone receptors
B) Directly blocks epithelial sodium channels (ENaC) in collecting duct
C) Inhibits carbonic anhydrase
D) Inhibits Na-K-ATPase

Answer: B - Amiloride and triamterene block ENaC in the collecting duct directly, independently of aldosterone. Spironolactone blocks aldosterone receptors. Both are potassium-sparing.

Q47. SGLT2 inhibitors (empagliflozin, dapagliflozin) reduce HF hospitalizations primarily through:

A) Positive inotropic effect
B) Osmotic diuresis and natriuresis reducing preload/afterload, plus cardioprotective mechanisms
C) Beta-1 blockade
D) ACE inhibition

Answer: B - SGLT2 inhibitors cause glucosuria-driven osmotic diuresis/natriuresis, reducing preload and afterload. Additional mechanisms include reduction in cardiac inflammation and fibrosis. They reduce HF hospitalizations in both HFrEF and HFpEF.

Q48. A patient develops acute gout, hyponatremia, and new-onset diabetes while on an antihypertensive. The most likely drug is:

A) Amlodipine
B) Hydrochlorothiazide
C) Losartan
D) Atenolol

Answer: B - Thiazides cause hyperuricemia (gout), hyponatremia (dilutional or direct effect), and hyperglycemia (impair insulin secretion). This metabolic triad is classic for thiazides.

SECTION 5: ANTICOAGULANTS (Q49-62)

Q49. Warfarin inhibits:

A) Factors Xa and IIa directly
B) Vitamin K epoxide reductase, preventing activation of factors II, VII, IX, X, and proteins C & S
C) Antithrombin III activation
D) Thrombin and fibrin cross-linking

Answer: B - Warfarin inhibits VKORC1 (vitamin K epoxide reductase complex), preventing recycling of vitamin K. This depletes active vitamin K needed to carboxylate clotting factors II, VII, IX, X, and proteins C and S.

Q50. A patient on warfarin has an INR of 8.5 with minor bleeding. The most appropriate management is:

A) Give fresh frozen plasma (FFP) immediately
B) Give IV vitamin K and hold warfarin
C) Give oral vitamin K and hold warfarin
D) Give protamine sulfate

Answer: C - For supratherapeutic INR with minor bleeding, oral vitamin K and warfarin hold is preferred. For serious/life-threatening bleeding, give IV vitamin K + 4-factor PCC (prothrombin complex concentrate) or FFP.

Q51. The reversal agent for unfractionated heparin is:

A) Vitamin K
B) Protamine sulfate
C) Idarucizumab
D) Andexanet alfa

Answer: B - Protamine sulfate (positively charged) binds and neutralizes heparin (negatively charged). 1 mg of protamine neutralizes ~100 units of heparin. It only partially reverses LMWH (~60%).

Q52. A patient with heparin-induced thrombocytopenia (HIT) develops a new clot. The drug of choice is:

A) Low-molecular-weight heparin (enoxaparin)
B) Warfarin immediately
C) Argatroban (direct thrombin inhibitor)
D) Platelet transfusion

Answer: C - In HIT, all heparin products (including LMWH) are contraindicated due to antibody cross-reactivity. Direct thrombin inhibitors (argatroban, bivalirudin) or fondaparinux are used. Warfarin should NOT be started until platelets recover (risk of warfarin-induced skin necrosis via protein C depletion).

Q53. Dabigatran's mechanism of action is:

A) Indirect thrombin inhibition via antithrombin
B) Direct thrombin (factor IIa) inhibitor
C) Direct factor Xa inhibitor
D) Vitamin K antagonist

Answer: B - Dabigatran is a direct oral anticoagulant (DOAC) that directly inhibits thrombin (factor IIa), preventing fibrin formation. Its reversal agent is idarucizumab (Praxbind).

Q54. Which DOAC requires dose reduction in patients with creatinine clearance (CrCl) of 15-50 mL/min for AF?

A) Rivaroxaban
B) Apixaban
C) Dabigatran
D) Warfarin

Answer: C - Dabigatran is 80% renally excreted. It requires dose reduction (110 mg BID) or avoidance (CrCl <15) in renal impairment. Apixaban is least dependent on renal clearance (~27% renal).

Q55. Fondaparinux differs from LMWH in that it:

A) Reverses with protamine
B) Is a synthetic pentasaccharide that selectively inhibits factor Xa via antithrombin, with NO effect on thrombin
C) Causes HIT more frequently
D) Is shorter acting than LMWH

Answer: B - Fondaparinux is a synthetic pentasaccharide that acts on antithrombin to specifically inhibit factor Xa only (not IIa). It does NOT cause HIT and is NOT reversed by protamine.

Q56. The reversal agent for rivaroxaban and apixaban overdose is:

A) Idarucizumab
B) Protamine sulfate
C) Andexanet alfa
D) Vitamin K

Answer: C - Andexanet alfa is a recombinant factor Xa decoy that reverses factor Xa inhibitors (rivaroxaban, apixaban, edoxaban). Idarucizumab reverses dabigatran.

Q57. A major drug interaction concern with warfarin is co-administration of:

A) Rifampin (strong CYP2C9 inducer)
B) Amlodipine
C) Atenolol
D) Furosemide

Answer: A - Rifampin strongly induces CYP2C9 (and CYP3A4), increasing warfarin metabolism and dramatically reducing INR. Dose of warfarin often needs to double. Many drugs interact with warfarin via CYP2C9.

Q58. Enoxaparin is classified as:

A) Unfractionated heparin (UFH)
B) Low-molecular-weight heparin (LMWH)
C) Direct thrombin inhibitor
D) Factor Xa inhibitor (direct)

Answer: B - Enoxaparin is a LMWH. It enhances antithrombin activity predominantly against factor Xa (anti-Xa:anti-IIa ratio ~3:1), unlike UFH which equally inhibits Xa and IIa (1:1).

Q59. Which patient should NOT receive a DOAC for AF?

A) Patient with CrCl of 60 mL/min
B) Patient with mechanical heart valve
C) Patient with prior stroke
D) Patient over 75 years old

Answer: B - DOACs are contraindicated in patients with mechanical heart valves (RE-ALIGN trial showed dabigatran increased strokes and bleeding vs warfarin in mechanical valves). Warfarin remains the anticoagulant of choice for mechanical valves.

Q60. The half-life of unfractionated heparin is approximately:

A) 2-4 hours (dose-dependent)
B) 12 hours
C) 24 hours
D) 3-5 days

Answer: A - UFH has a short, dose-dependent half-life of ~1-2 hours at therapeutic doses (can be 0.5-2.5 hours). This allows rapid reversal but requires continuous IV infusion.

Q61. Warfarin's effect is monitored by INR. The target INR for a patient with AF is:

A) 1.5-2.0
B) 2.0-3.0
C) 2.5-3.5
D) 3.0-4.0

Answer: B - INR 2.0-3.0 is the target for AF, DVT/PE treatment, and bioprosthetic valve. INR 2.5-3.5 is for mechanical mitral valves or high-risk mechanical aortic valves.

Q62. Bivalirudin differs from argatroban in that bivalirudin:

A) Is hepatically metabolized (preferred in hepatic failure)
B) Is cleared by enzymatic cleavage and kidneys (preferred in hepatic failure)
C) Has a longer half-life
D) Causes more bleeding

Answer: B - Bivalirudin is cleared both enzymatically (proteolysis) and renally. Argatroban is hepatically metabolized and preferred in renal failure. Bivalirudin is preferred when hepatic function is impaired.

SECTION 6: ANTIARRHYTHMICS (Q63-78)

Q63. The Vaughan Williams class of amiodarone is:

A) Class I (sodium channel blocker)
B) Class II (beta-blocker)
C) Class III (potassium channel blocker)
D) Class IV (calcium channel blocker)

Answer: C - Amiodarone is primarily a Class III antiarrhythmic (blocks K+ channels, prolongs action potential). However, it also has Class I (Na+ block), Class II (beta-block), and Class IV (Ca2+ block) properties.

Q64. A patient on long-term amiodarone for AF develops progressive dyspnea and bilateral pulmonary infiltrates. The most likely diagnosis is:

A) Community-acquired pneumonia
B) Amiodarone pulmonary toxicity
C) Acute decompensated heart failure
D) Pulmonary embolism

Answer: B - Amiodarone pulmonary toxicity (incidence 1-5%/year) presents with dyspnea, cough, bilateral infiltrates, and elevated DLCO. It requires drug discontinuation and may need corticosteroids.

Q65. Which adverse effect of amiodarone is monitored by thyroid function tests?

A) Both hypothyroidism and hyperthyroidism
B) Hypothyroidism only
C) Hyperthyroidism only
D) Thyroid cancer

Answer: A - Amiodarone contains ~37% iodine by weight. It can cause BOTH hypothyroidism (most common in iodine-sufficient areas, via Wolff-Chaikoff effect) and hyperthyroidism (in iodine-deficient areas). Both require monitoring.

Q66. A Class Ic antiarrhythmic drug (flecainide) is CONTRAINDICATED in patients with:

A) Atrial fibrillation alone
B) Structural heart disease or post-MI (CAST trial)
C) Supraventricular tachycardia
D) Wolff-Parkinson-White syndrome

Answer: B - The CAST trial (Cardiac Arrhythmia Suppression Trial) showed that flecainide and encainide increased mortality in post-MI patients with asymptomatic PVCs, despite suppressing arrhythmias. Class Ic drugs are now contraindicated in structural heart disease and post-MI.

Q67. Adenosine is used in the acute management of:

A) Ventricular fibrillation
B) Paroxysmal supraventricular tachycardia (PSVT)
C) Atrial flutter
D) Torsades de pointes

Answer: B - Adenosine causes transient AV nodal block (seconds) by activating A1 receptors, terminating reentrant SVT that involves the AV node. It has an extremely short half-life (<10 seconds).

Q68. The mechanism of adenosine includes:

A) Increasing cAMP in SA node
B) Hyperpolarizing SA and AV nodal cells by opening K+ channels and reducing Ca2+ influx
C) Blocking Na+ channels
D) Blocking beta receptors

Answer: B - Adenosine activates A1 receptors coupled to Gi protein. This opens GIRK (G-protein coupled inward rectifying K+) channels (hyperpolarization) and inhibits If current, causing marked AV nodal slowing.

Q69. The drug most likely to cause Torsades de Pointes (TdP) is:

A) Metoprolol
B) Sotalol
C) Lidocaine
D) Phenytoin

Answer: B - Sotalol (Class III/beta-blocker hybrid) prolongs the QT interval by blocking IKr potassium channels. QT prolongation predisposes to TdP, a polymorphic ventricular tachycardia. Other TdP-causing drugs: quinidine, dofetilide, haloperidol, erythromycin.

Q70. Treatment of Torsades de Pointes is:

A) Amiodarone IV
B) IV magnesium sulfate and correct underlying cause
C) Lidocaine IV
D) Adenosine IV

Answer: B - IV magnesium sulfate (2g) is first-line for TdP, even in normal Mg2+ levels. It stabilizes cardiac membranes. Also remove offending drug, correct hypokalemia/hypomagnesemia, and use isoproterenol or pacing to increase heart rate (shortens QT).

Q71. Quinidine's most serious adverse effect affecting the GI system is:

A) Hepatotoxicity
B) Cinchonism (tinnitus, headache, GI upset)
C) Colitis
D) Pancreatitis

Answer: B - "Cinchonism" refers to the syndrome of tinnitus, headache, visual disturbances, and GI upset caused by quinidine (and other cinchona alkaloids). At high doses, it causes serious arrhythmias (TdP).

Q72. Lidocaine is preferred over other antiarrhythmics in:

A) Atrial fibrillation
B) Acute ventricular arrhythmias post-MI (IV)
C) SVT
D) AV block

Answer: B - IV lidocaine is a Class Ib antiarrhythmic that preferentially blocks inactivated Na+ channels in ischemic tissue. It is used for acute ventricular arrhythmias. However, amiodarone is now preferred for shock-refractory VF/VT.

Q73. Digoxin at high doses causes arrhythmias primarily by:

A) Prolonging the QT interval
B) Inhibiting Na-K-ATPase leading to increased intracellular Ca2+, causing delayed afterdepolarizations and DADs
C) Blocking potassium channels
D) Blocking sodium channels

Answer: B - Digoxin inhibits Na-K-ATPase. Na+ accumulates intracellularly, and the Na-Ca exchanger (NCX) extrudes Na+ while bringing in Ca2+. Excess intracellular Ca2+ causes spontaneous depolarizations (DADs), leading to triggered arrhythmias (PAT with AV block, PVCs, VT/VF).

Q74. A digoxin-toxic patient on digoxin who developed ventricular tachycardia should be treated with:

A) DC cardioversion (preferred)
B) Digoxin-immune Fab fragments (DigiFab)
C) Calcium gluconate IV
D) Quinidine

Answer: B - Digoxin-immune Fab fragments (DigiFab) are the antidote for life-threatening digoxin toxicity. DC cardioversion should be avoided if possible (can cause intractable VF in digoxin toxicity). Calcium is contraindicated (worsens digoxin toxicity - "stone heart").

Q75. Amiodarone is the only antiarrhythmic drug that:

A) Is safe in heart failure with reduced EF
B) Requires no monitoring
C) Has both atrial and ventricular efficacy with no proarrhythmic risk
D) Is purely a Class III agent

Answer: A - Amiodarone is the only antiarrhythmic drug considered safe in patients with structural heart disease and HFrEF. Most other antiarrhythmics (Class I, sotalol) increase mortality in this population.

Q76. Dronedarone (a non-iodinated analog of amiodarone) is contraindicated in:

A) Persistent AF
B) Paroxysmal AF with normal EF
C) Permanent AF or patients with recent decompensated HF (PALLAS/ANDROMEDA trials)
D) Thyroid disease

Answer: C - The ANDROMEDA trial showed dronedarone increased mortality in patients with severe HF. The PALLAS trial showed increased stroke, MI, and death in permanent AF. Dronedarone is contraindicated in permanent AF and NYHA class III-IV HF.

Q77. Ibutilide is used for:

A) Chronic suppression of AF
B) Acute chemical cardioversion of AF or atrial flutter
C) Rate control in AF
D) Ventricular arrhythmia suppression

Answer: B - Ibutilide (Class III) is given IV for chemical cardioversion of AF and atrial flutter. It is more effective for flutter (~60%) than AF (~30%). Risk of TdP is ~4-8%; cardiac monitoring required for 4 hours post-infusion.

Q78. The effect of hypokalemia on digoxin toxicity is:

A) Decreased toxicity (K+ competes with digoxin at receptor)
B) Increased toxicity (K+ normally competes with digoxin for Na-K-ATPase binding)
C) No effect
D) Only affects renal clearance

Answer: B - Potassium competes with digoxin at the Na-K-ATPase binding site. Hypokalemia removes competitive inhibition, effectively increasing digoxin's binding and toxicity. Loop diuretics, which cause hypokalemia, increase digoxin toxicity risk.

SECTION 7: LIPID-LOWERING DRUGS (Q79-90)

Q79. Statins work by inhibiting:

A) Lipoprotein lipase
B) HMG-CoA reductase (rate-limiting step in cholesterol synthesis)
C) PCSK9 (proprotein convertase subtilisin/kexin type 9)
D) Bile acid absorption in the gut

Answer: B - Statins competitively inhibit HMG-CoA reductase, reducing hepatic cholesterol synthesis. This upregulates LDL receptors on hepatocytes, increasing LDL clearance from the blood.

Q80. A patient on simvastatin is started on clarithromycin. Statin dose should be:

A) Doubled
B) Halved
C) Withheld during antibiotic course due to CYP3A4 inhibition increasing statin levels
D) No change required

Answer: C - Clarithromycin is a strong CYP3A4 inhibitor. Simvastatin is a CYP3A4 substrate. Inhibition increases simvastatin levels dramatically, increasing risk of myopathy/rhabdomyolysis. Simvastatin should be withheld.

Q81. A patient on a statin develops severe muscle pain with markedly elevated CK (>10x ULN) and myoglobinuria. The most appropriate action is:

A) Reduce statin dose
B) Switch to a different statin
C) Discontinue statin immediately and provide IV hydration
D) Add coenzyme Q10

Answer: C - Rhabdomyolysis requires immediate statin discontinuation and aggressive IV fluid hydration to prevent myoglobinuric acute renal failure. CK >10x ULN with symptoms is diagnostic of myopathy, and rhabdomyolysis is life-threatening.

Q82. Which statin has the highest potency (greatest LDL reduction per dose)?

A) Simvastatin
B) Lovastatin
C) Rosuvastatin
D) Pravastatin

Answer: C - Rosuvastatin (and atorvastatin) are the most potent statins. Rosuvastatin 10-40 mg reduces LDL by 46-55%. It is a hydrophilic statin with less CYP3A4 metabolism, reducing some drug interactions.

Q83. The mechanism of PCSK9 inhibitors (evolocumab, alirocumab) is:

A) HMG-CoA reductase inhibition
B) Blocking PCSK9, which normally degrades LDL receptors, thereby increasing LDL receptor availability
C) Inhibiting bile acid reabsorption
D) Activating PPAR-alpha receptors

Answer: B - PCSK9 normally binds LDL receptors and targets them for degradation. Blocking PCSK9 with monoclonal antibodies increases LDL receptor recycling back to the hepatocyte surface, dramatically lowering LDL (by 50-70% on top of statin therapy).

Q84. Niacin (nicotinic acid) lowers triglycerides and raises HDL. Its most common side effect is:

A) Myopathy
B) Flushing (prostaglandin-mediated)
C) Constipation
D) Hepatotoxicity

Answer: B - Niacin causes prostaglandin D2-mediated flushing and itching, especially after first dose or dose increase. Taking aspirin 30 minutes before niacin reduces flushing. Extended-release forms also reduce flushing.

Q85. Fibrates (gemfibrozil, fenofibrate) work primarily by:

A) Inhibiting cholesterol synthesis
B) Activating PPAR-alpha receptors, increasing lipoprotein lipase activity and reducing triglyceride production
C) Blocking bile acid reabsorption
D) Inhibiting PCSK9

Answer: B - Fibrates activate PPAR-alpha receptors in hepatocytes and muscles, increasing lipoprotein lipase synthesis (TG clearance), reducing VLDL production, and modestly increasing HDL. Best for hypertriglyceridemia.

Q86. Ezetimibe reduces LDL by:

A) Inhibiting HMG-CoA reductase
B) Blocking NPC1L1 transporter in intestinal brush border, reducing cholesterol absorption
C) Increasing bile acid excretion
D) Increasing LDL receptor expression

Answer: B - Ezetimibe selectively inhibits NPC1L1 (Niemann-Pick C1-like 1) protein in the intestinal brush border, reducing dietary and biliary cholesterol absorption by ~50%. It reduces LDL by ~15-20% and is often combined with statins.

Q87. Bile acid sequestrants (cholestyramine, colesevelam) interact with which drugs?

A) Decrease absorption of warfarin, digoxin, thyroid hormones, and fat-soluble vitamins
B) Increase absorption of fat-soluble vitamins
C) Increase warfarin effect
D) No significant interactions

Answer: A - Bile acid sequestrants bind many drugs and vitamins in the GI tract, reducing their absorption. Other drugs should be taken 1 hour before or 4 hours after sequestrant administration.

Q88. Which statin is most appropriate for a patient with severe renal failure (CrCl <10 mL/min)?

A) Rosuvastatin (requires dose reduction in severe CKD)
B) Atorvastatin (primarily hepatic elimination, safe in CKD)
C) Simvastatin at half dose
D) Pravastatin without change

Answer: B - Atorvastatin is primarily hepatically metabolized and eliminated in bile, making it safe in renal failure without dose adjustment. Rosuvastatin requires dose reduction in severe CKD.

Q89. The ACC/AHA guidelines recommend high-intensity statin therapy (achieving ≥50% LDL reduction) for all of the following EXCEPT:

A) Clinical ASCVD (history of MI, stroke, or peripheral artery disease)
B) LDL ≥190 mg/dL (familial hypercholesterolemia)
C) Isolated hypertriglyceridemia without other risk factors
D) Diabetes aged 40-75 with 10-year risk ≥7.5%

Answer: C - Isolated hypertriglyceridemia without ASCVD risk is not an indication for high-intensity statin. Statins are less effective for hypertriglyceridemia; fibrates and omega-3 fatty acids are preferred.

Q90. Inclisiran is a newer lipid-lowering agent that differs from PCSK9 inhibitors in that it:

A) Blocks the PCSK9 protein extracellularly
B) Is an siRNA that silences PCSK9 gene expression in hepatocytes, requiring only twice-yearly dosing
C) Is an oral tablet
D) Also inhibits HMG-CoA reductase

Answer: B - Inclisiran is a small interfering RNA (siRNA) that targets PCSK9 mRNA in hepatocytes, preventing PCSK9 synthesis. It achieves 50% LDL reduction with only twice-yearly subcutaneous injections after initial doses.

SECTION 8: ANTIANGINALS & ACUTE CORONARY SYNDROME (Q91-105)

Q91. A patient with stable angina experiences severe hypotension and syncope after taking sildenafil followed by nitroglycerin. The mechanism is:

A) Additive sodium retention
B) Severe hypotension from additive cGMP-mediated vasodilation
C) Drug-induced myocardial depression
D) Reflex bradycardia

Answer: B - Both nitrates (which increase cGMP via NO) and PDE5 inhibitors (which prevent cGMP breakdown) cause vasodilation via cGMP. Together they cause profound, potentially fatal hypotension. PDE5 inhibitors are absolutely contraindicated within 24 hours of nitrates (48 hours for tadalafil).

Q92. The mechanism of nitrate tolerance and how to prevent it:

A) Downregulation of guanylyl cyclase; prevented by ACE inhibitors
B) Depletion of intracellular sulfhydryl groups and mitochondrial aldehyde dehydrogenase-2 (ALDH2) impairment; prevented by a nitrate-free interval of 8-12 hours
C) Accumulation of toxic metabolites; prevented by antioxidants
D) Increased nitrate metabolism; prevented by CYP inhibitors

Answer: B - Continuous nitrate exposure depletes -SH groups needed for NO generation and impairs ALDH2. A daily nitrate-free interval of 8-12 hours (usually overnight) prevents tolerance. During this interval, angina may worsen ("rebound angina").

Q93. Ranolazine's mechanism of anti-anginal action is unique because it:

A) Reduces heart rate via If channel blockade
B) Inhibits late inward sodium current (late INa), reducing Ca2+ overload in ischemic myocardium
C) Blocks L-type calcium channels
D) Acts as a nitric oxide donor

Answer: B - Ranolazine inhibits the late inward Na+ current (late INa) in ischemic cardiomyocytes. This prevents Na-overload-driven Ca2+ overload (via NCX), reducing wall tension and ischemia. It does not reduce BP or HR significantly.

Q94. Ivabradine reduces angina by:

A) Blocking beta receptors
B) Selectively inhibiting the If (funny current) in SA node, reducing heart rate WITHOUT negative inotropy
C) Vasodilation
D) Reducing afterload

Answer: B - Ivabradine selectively blocks HCN channels (If current) in the SA node, reducing heart rate (pure chronotropic effect). Unlike beta-blockers, it has no effect on contractility, AV conduction, or blood pressure.

Q95. The current standard of care for STEMI within the first 12 hours includes:

A) IV thrombolytics only
B) Primary percutaneous coronary intervention (PCI) if available within 90 minutes, or fibrinolytics if PCI unavailable within 120 minutes
C) Aspirin alone
D) IV heparin infusion only

Answer: B - Primary PCI (door-to-balloon time <90 min) is preferred for STEMI. If PCI is not available within 120 minutes of first medical contact, fibrinolysis (tPA, tenecteplase) should be given within 30 minutes.

Q96. Dual antiplatelet therapy (DAPT) after drug-eluting stent (DES) placement typically consists of:

A) Aspirin + warfarin for 6 months
B) Aspirin + P2Y12 inhibitor (clopidogrel, ticagrelor, or prasugrel) for at least 6-12 months
C) Aspirin + GP IIb/IIIa inhibitor for 12 months
D) Aspirin alone for 12 months

Answer: B - After DES, DAPT with aspirin + a P2Y12 inhibitor (clopidogrel 75 mg, ticagrelor 90 mg BID, or prasugrel 10 mg) reduces stent thrombosis. Duration is at least 6-12 months for non-ACS DES; 12 months for ACS-DES.

Q97. Clopidogrel is a prodrug. Its activation is impaired in patients with:

A) CYP3A4 poor metabolizers
B) CYP2C19 poor metabolizers (loss-of-function polymorphisms)
C) CYP2D6 poor metabolizers
D) CYP1A2 poor metabolizers

Answer: B - Clopidogrel requires CYP2C19 for bioactivation to its active thiol metabolite. CYP2C19 poor metabolizers (~2-14% of population by ethnicity) have inadequate platelet inhibition and higher cardiovascular event rates with clopidogrel.

Q98. Ticagrelor's major advantage over clopidogrel is:

A) It requires no activation (direct-acting)
B) More potent, consistent platelet inhibition regardless of CYP2C19 status
C) It is given once daily
D) Lower bleeding risk

Answer: B - Ticagrelor is a direct-acting (non-prodrug) P2Y12 inhibitor with reversible binding, providing more consistent and potent platelet inhibition than clopidogrel. PLATO trial showed superior outcomes in ACS vs clopidogrel.

Q99. A unique side effect of ticagrelor not seen with clopidogrel is:

A) Thrombocytopenic purpura
B) Dyspnea (adenosine-mediated) and bradycardia
C) Rash
D) Hepatotoxicity

Answer: B - Ticagrelor inhibits adenosine reuptake (as an off-target effect), increasing local adenosine. This causes dyspnea (~15% of patients) and ventricular pauses/bradycardia. Dyspnea is the most common reason for discontinuation.

Q100. Prasugrel should NOT be used in:

A) Patients with ACS undergoing PCI
B) Patients aged ≥75 years, weight <60 kg, or prior stroke/TIA (net clinical harm)
C) Patients on aspirin
D) Patients with renal impairment

Answer: B - The TRITON-TIMI trial excluded and warned against prasugrel in patients ≥75 years, <60 kg body weight, and with prior stroke/TIA due to excess bleeding that outweighs the benefit. These are labeled contraindications/warnings.

Q101. Streptokinase differs from alteplase (tPA) in that streptokinase:

A) Is fibrin-selective
B) Is non-fibrin-selective, causes systemic fibrinolysis, and is antigenic (cannot be re-used within 12 months)
C) Has a shorter half-life
D) Requires concomitant heparin

Answer: B - Streptokinase is a non-fibrin-specific thrombolytic that activates both bound and free plasminogen, causing systemic fibrinolytic state. It is antigenic (streptococcal protein) and should not be re-administered within 6-12 months. tPA is fibrin-selective and non-antigenic.

Q102. The ABSOLUTE contraindication to thrombolytic therapy includes:

A) Age >75 years
B) Uncontrolled hypertension at presentation (BP 185/110 mmHg)
C) Prior intracranial hemorrhage
D) Recent surgery (>3 months ago)

Answer: C - Prior intracranial hemorrhage (at ANY time) is an absolute contraindication. Recent major surgery <3 months, known AVM/malignancy, and active internal bleeding (not menses) are also absolute contraindications.

Q103. Abciximab is a GP IIb/IIIa inhibitor that works by:

A) Blocking ADP receptors on platelets
B) Blocking the final common pathway of platelet aggregation (fibrinogen binding to GPIIb/IIIa)
C) Inhibiting cyclooxygenase
D) Activating protein C

Answer: B - GPIIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban) block the fibrinogen receptor on platelets, preventing cross-linking and aggregation regardless of the initial stimulus (thrombin, ADP, collagen, etc.).

Q104. Aspirin irreversibly inhibits COX-1 in platelets. The duration of its antiplatelet effect is:

A) 24 hours
B) 3-5 days
C) 7-10 days (platelet lifespan)
D) 14 days

Answer: C - Platelets are anucleate and cannot synthesize new COX. Aspirin's acetylation of COX-1 is irreversible. Platelet function is only restored when new platelets are produced (7-10 days, average ~10% new platelets per day).

Q105. The main limitation of morphine use in STEMI is:

A) Respiratory depression
B) Delayed absorption and reduced efficacy of oral P2Y12 inhibitors (clopidogrel, ticagrelor)
C) Increasing heart rate
D) Coronary vasoconstriction

Answer: B - The CRUSADE and other registry data showed morphine in ACS is associated with delayed and reduced absorption of oral P2Y12 inhibitors (decreased gut motility). This may contribute to inadequate platelet inhibition during PCI.

SECTION 9: HEART FAILURE PHARMACOLOGY (Q106-118)

Q106. Digoxin is used in heart failure primarily to:

A) Improve survival
B) Improve symptoms and reduce hospitalizations (but no mortality benefit - DIG trial)
C) Reverse cardiac remodeling
D) Reduce ventricular hypertrophy

Answer: B - The DIG trial showed digoxin reduces HF symptoms and hospitalizations but does NOT improve mortality. It remains useful for symptom control in HFrEF patients on optimal medical therapy.

Q107. The therapeutic index of digoxin is:

A) Wide (therapeutic range 5-10 ng/mL)
B) Narrow (therapeutic range 0.5-0.9 ng/mL for HF; toxicity >2 ng/mL)
C) Wide with no toxicity concerns
D) Only relevant in overdose

Answer: B - Digoxin has a very narrow therapeutic index. For HF, the target serum level is 0.5-0.9 ng/mL (lower than previously used). Toxicity occurs at >2 ng/mL, though toxicity can occur at lower levels with hypokalemia or hypomagnesemia.

Q108. Sacubitril/valsartan (ARNI) is contraindicated with:

A) Beta-blockers
B) Loop diuretics
C) ACE inhibitors (even with 36-hour washout - angioedema risk)
D) Aldosterone antagonists

Answer: C - ARNI must not be combined with ACE inhibitors because neprilysin inhibition + ACE inhibition dramatically increases bradykinin, causing angioedema. A 36-hour washout after stopping ACE inhibitor is required before starting ARNI.

Q109. The four pillars of HFrEF therapy with mortality benefit are:

A) Digoxin, diuretics, hydralazine, nitrates
B) ACE inhibitor/ARB/ARNI + beta-blocker + MRA (aldosterone antagonist) + SGLT2 inhibitor
C) Statins, aspirin, ACE inhibitors, beta-blockers
D) Amiodarone, beta-blockers, diuretics, digoxin

Answer: B - The current four pillars of HFrEF therapy with proven mortality benefit are: RAAS blocker (ACEi/ARB or ARNI), beta-blocker, mineralocorticoid receptor antagonist (MRA), and SGLT2 inhibitor.

Q110. Hydralazine + isosorbide dinitrate combination in HF is:

A) First-line therapy for all HF patients
B) Specifically indicated for self-identified Black patients who remain symptomatic despite optimal therapy (A-HeFT trial)
C) Used only in acute decompensated HF
D) An alternative to digoxin in HFpEF

Answer: B - The A-HeFT trial demonstrated mortality benefit of hydralazine/isosorbide dinitrate in self-identified Black patients with HFrEF on standard therapy. It is also used when ACEi/ARB/ARNI are not tolerated (e.g., renal failure, hyperkalemia).

Q111. Dobutamine, used in acute decompensated heart failure, acts on:

A) Alpha-1 receptors causing vasoconstriction
B) Beta-1 receptors primarily, increasing cardiac contractility and cardiac output
C) Dopamine receptors in the kidney
D) Beta-2 receptors causing bronchodilation

Answer: B - Dobutamine is a synthetic catecholamine that primarily stimulates beta-1 receptors, increasing myocardial contractility, heart rate, and CO. It has mild beta-2 vasodilating effects, reducing afterload slightly. Used for cardiogenic shock and acute decompensated HF.

Q112. A patient with acute decompensated HF is given a drug that causes bright red skin, flushing, and hypotension. The drug is most likely:

A) Furosemide
B) Nesiritide
C) Morphine
D) Dobutamine

Answer: B - Nesiritide (recombinant BNP) is a vasodilator/diuretic used in ADHF. Its side effects include hypotension and flushing. Its use has declined due to concerns about renal toxicity (ASCEND-HF trial).

Q113. Milrinone works by:

A) Stimulating beta-1 adrenergic receptors
B) Inhibiting phosphodiesterase-3 (PDE3), increasing cAMP and calcium in cardiomyocytes
C) Blocking sodium-calcium exchanger
D) Activating adenylyl cyclase directly

Answer: B - Milrinone is a PDE3 inhibitor ("inodilator"). By blocking cAMP breakdown, it increases contractility (positive inotropy) and vasodilation (reducing afterload). It is a "calcium sensitizer" in effect. Side effects include arrhythmias and hypotension.

Q114. Patients with HFpEF (preserved ejection fraction) show mortality benefit from:

A) ACE inhibitors and beta-blockers (same as HFrEF)
B) SGLT2 inhibitors (dapagliflozin - EMPEROR-Preserved/DELIVER trials) and symptom management
C) Aldosterone antagonists (proven mortality benefit)
D) Digoxin

Answer: B - HFpEF has limited evidence for mortality reduction. EMPEROR-Preserved and DELIVER trials showed SGLT2 inhibitors (empagliflozin, dapagliflozin) reduce HF hospitalizations in HFpEF. Most other HFrEF therapies have not shown mortality benefit in HFpEF.

Q115. Carvedilol should NOT be initiated in which HF patient?

A) Stable HF, NYHA class II with HR 80 bpm
B) Acute decompensated heart failure requiring IV inotropes
C) Chronic HF with HR 68 bpm on ACEi and diuretics
D) Post-MI with EF 30%

Answer: B - Beta-blockers are contraindicated in acute decompensated HF that requires inotropic support. They should only be initiated in stable, euvolemic HF patients (typically at low doses and titrated slowly).

Q116. The hemodynamic goal of therapy in cardiogenic shock includes which drug combination?

A) Furosemide + hydralazine
B) Vasopressors (norepinephrine as preferred) + inotropes (dobutamine/milrinone) + mechanical circulatory support
C) Vasodilators + digoxin
D) ACEi + ARB + diuretic

Answer: B - Cardiogenic shock management: norepinephrine is preferred vasopressor (SOAP II trial), dobutamine/milrinone for inotropic support, and mechanical circulatory support (IABP, Impella, ECMO) in refractory cases.

Q117. A patient with HFrEF on enalapril develops productive cough. The best switch is:

A) Losartan 50mg daily
B) Sacubitril/valsartan 49/51 mg BID (after 36-hour washout)
C) Candesartan 16 mg daily
D) Either A or C; choose based on co-morbidities

Answer: B - Current HF guidelines recommend switching from ACEi to sacubitril/valsartan (ARNI) in symptomatic HFrEF patients who tolerate ACEi/ARB (PARADIGM-HF showed 20% relative risk reduction in CV death/HF hospitalization). After 36-hour washout.

Q118. Which drug should be AVOIDED in HFrEF?

A) Carvedilol
B) Thiazolidinediones (pioglitazone, rosiglitazone)
C) Spironolactone
D) Sacubitril/valsartan

Answer: B - Thiazolidinediones cause sodium/water retention and are known to worsen or precipitate HF. They are contraindicated in patients with HF (NYHA class III-IV). NSAIDs, most CCBs (except amlodipine/felodipine), and most antiarrhythmics are also harmful in HF.

SECTION 10: HYPERTENSION & SPECIAL POPULATIONS (Q119-132)

Q119. First-line antihypertensive therapy in a patient with hypertension and CKD with proteinuria is:

A) Amlodipine + thiazide
B) ACE inhibitor or ARB
C) Beta-blocker
D) Loop diuretic

Answer: B - ACEi/ARBs are first-line in CKD with proteinuria because they reduce intraglomerular pressure and proteinuria independently of BP reduction, slowing progression.

Q120. A hypertensive emergency requires:

A) Immediate BP reduction to <120/80 within 1 hour using oral medications
B) Controlled BP reduction of ~25% in the first hour with IV agents, then gradual normalization over 24-48 hours
C) Rapid normalization to normal BP within 15 minutes
D) Oral antihypertensives with admission for monitoring

Answer: B - Lowering BP too rapidly in hypertensive emergency can cause ischemic stroke, MI, or blindness (watershed infarcts). The guideline is: reduce MAP by ~10-25% in the first hour, then to ~160/100 over next 2-6 hours, then gradually to normal.

Q121. Sodium nitroprusside's toxicity in prolonged infusion is due to:

A) Cyanide accumulation (metabolized to cyanide and thiocyanate)
B) Methemoglobin formation
C) Direct renal toxicity
D) Hypertensive rebound

Answer: A - Sodium nitroprusside is metabolized to cyanide in the blood, then to thiocyanate in the liver. Prolonged infusion (>72h), high doses, or renal failure (thiocyanate accumulation) can cause cyanide toxicity (tachyphylaxis, lactic acidosis). Hydroxocobalamin is the antidote.

Q122. Drug of choice for hypertension in pregnancy:

A) ACE inhibitors
B) ARBs
C) Labetalol, nifedipine, and methyldopa
D) Hydrochlorothiazide

Answer: C - ACEi and ARBs are teratogenic (Category D/X). Safe antihypertensives in pregnancy: labetalol (IV for acute), oral nifedipine, methyldopa. For severe hypertension (BP ≥160/110), IV labetalol or IV hydralazine are first-line.

Q123. The most likely cause of hypertension in a young woman with hypokalemia, metabolic alkalosis, and an adrenal mass on CT scan is:

A) Pheochromocytoma
B) Primary hyperaldosteronism (Conn's syndrome)
C) Renovascular hypertension
D) Cushing's syndrome

Answer: B - Primary hyperaldosteronism (Conn's) presents with hypertension, hypokalemia, and metabolic alkalosis. It is the most common secondary cause of hypertension. Spironolactone or eplerenone (aldosterone antagonists) are the drugs of choice.

Q124. Drug of choice for hypertension in pheochromocytoma (pre-operative management):

A) Non-selective beta-blocker (propranolol) first
B) Alpha-blocker first (phenoxybenzamine or prazosin), THEN beta-blocker after adequate alpha blockade
C) CCB first
D) ACE inhibitor first

Answer: B - In pheochromocytoma, ALWAYS start alpha-blocker first (phenoxybenzamine for 1-2 weeks pre-op). Starting beta-blockers first causes paradoxical hypertension by blocking beta-2 vasodilatory reflexes while alpha-mediated vasoconstriction is unopposed.

Q125. Clonidine causes withdrawal hypertension when abruptly stopped because:

A) Alpha-1 receptor upregulation
B) Alpha-2 receptor downregulation during therapy leads to excess norepinephrine release on withdrawal
C) Increased renin secretion
D) Sodium and water retention

Answer: B - Chronic clonidine therapy downregulates central alpha-2 receptors. Abrupt withdrawal causes rebound sympathetic activation with severe hypertension, tachycardia, and anxiety - similar to pheochromocytoma crisis. Must taper clonidine slowly.

Q126. Resistant hypertension is defined as:

A) BP >140/90 despite 2 medications
B) BP above target despite optimal doses of 3 antihypertensives of different classes (including a diuretic), after excluding pseudoresistance
C) BP >180/120 at any time
D) Failure of 4 or more medications

Answer: B - Resistant hypertension: BP above target on 3 optimally dosed antihypertensives including a diuretic. Renal denervation and spironolactone (as 4th agent) show benefit in resistant hypertension.

Q127. The antihypertensive least likely to cause metabolic side effects is:

A) Hydrochlorothiazide
B) Atenolol
C) Amlodipine
D) Chlorthalidone

Answer: C - Amlodipine (CCB) has a neutral metabolic profile - no effects on glucose, lipids, uric acid, or electrolytes. Beta-blockers and thiazides both worsen glucose/lipid profiles.

Q128. White coat hypertension is best identified by:

A) Repeated office measurements
B) 24-hour ambulatory BP monitoring (ABPM)
C) Home BP monitoring
D) Echocardiography

Answer: B - 24-hour ABPM is the gold standard for diagnosing white coat hypertension (elevated office BP, normal out-of-office BP). Home BP monitoring is the second-best option.

Q129. Thiazide diuretics are preferred over loop diuretics in hypertension because:

A) Thiazides are more potent diuretics
B) Thiazides reduce peripheral vascular resistance with long-term use (beyond simple diuresis)
C) Loop diuretics cause bradycardia
D) Thiazides work better in CKD

Answer: B - With long-term use, thiazides lose much of their diuretic effect but maintain antihypertensive efficacy by reducing peripheral vascular resistance (possibly via vasodilation through K+ channel opening). In CKD (GFR <30), thiazides lose effectiveness; use loop diuretics.

Q130. The Eighth Joint National Committee (JNC 8) recommended BP target for adults aged ≥60 without diabetes or CKD is:

A) <120/80 mmHg
B) <140/90 mmHg
C) <150/90 mmHg
D) <160/90 mmHg

Answer: C - JNC 8 raised the BP target for adults ≥60 to <150/90 mmHg. However, later guidelines (ACC/AHA 2017) define hypertension as ≥130/80 and set targets of <130/80 for most patients, creating controversy.

Q131. Minoxidil causes reflex tachycardia and requires co-administration with:

A) ACE inhibitor and loop diuretic
B) Beta-blocker (to prevent reflex tachycardia) and a loop diuretic (to prevent fluid retention)
C) Alpha-blocker and thiazide
D) ARB and spironolactone

Answer: B - Minoxidil (potent direct vasodilator) causes reflex SNS activation (tachycardia) and fluid retention. Must be used with a beta-blocker AND a loop diuretic. Side effect: hypertrichosis (hair growth - basis for Rogaine).

Q132. Drug-induced hypertension can be caused by all of the following EXCEPT:

A) NSAIDs
B) Oral contraceptives (estrogen)
C) Erythropoietin
D) Furosemide

Answer: D - Furosemide LOWERS BP (it is an antihypertensive). Common causes of drug-induced hypertension: NSAIDs (retain Na+), OCPs (estrogen increases renin-angiotensin), erythropoietin (vasoconstriction + increased viscosity), cocaine, sympathomimetics, calcineurin inhibitors.

SECTION 11: MISCELLANEOUS HIGH-YIELD CARDIOLOGY (Q133-150)

Q133. The most common cause of sudden cardiac death (SCD) in young athletes is:

A) Wolff-Parkinson-White syndrome
B) Hypertrophic cardiomyopathy (HCM)
C) Dilated cardiomyopathy
D) Long QT syndrome

Answer: B - Hypertrophic cardiomyopathy is the most common cause of SCD in young athletes in the United States. It is characterized by asymmetric septal hypertrophy, systolic anterior motion of mitral valve, and LVOT obstruction.

Q134. Disopyramide is used in hypertrophic obstructive cardiomyopathy (HOCM) because it:

A) Reduces LVH
B) Negative inotropy reduces LVOT obstruction
C) Causes vasodilation
D) Prolongs diastolic filling time

Answer: B - Disopyramide (Class Ia antiarrhythmic with significant negative inotropic and anticholinergic effects) reduces LVOT obstruction in HOCM by decreasing contractility of the hypertrophied septum, reducing dynamic obstruction.

Q135. A patient with Wolff-Parkinson-White (WPW) syndrome in AF should NOT receive:

A) Electrical cardioversion
B) Amiodarone (controversial)
C) AV nodal blocking drugs: adenosine, verapamil, digoxin
D) Procainamide

Answer: C - In WPW with AF, AV nodal blockers (adenosine, verapamil, diltiazem, digoxin, beta-blockers) are CONTRAINDICATED. They block the AV node, forcing all conduction down the accessory pathway, potentially causing ventricular fibrillation. Use procainamide or electrical cardioversion.

Q136. The drug of choice for stable wide-complex tachycardia (presumed VT) in a patient with a pulse is:

A) Adenosine
B) Verapamil
C) Procainamide or amiodarone IV
D) Lidocaine

Answer: C - For stable hemodynamic VT: procainamide (preferred per ACLS) or amiodarone IV. Lidocaine is an alternative. Adenosine and verapamil are dangerous if the wide-complex tachycardia is VT (or WPW with AF), as they can precipitate hemodynamic collapse.

Q137. The drug most useful in reducing the risk of sudden cardiac death (SCD) in patients post-MI with reduced EF is:

A) Digoxin
B) Class I antiarrhythmics (flecainide, encainide)
C) Implantable cardioverter-defibrillator (ICD) + beta-blocker
D) Amiodarone alone

Answer: C - ICD therapy is the most effective intervention for primary prevention of SCD in HFrEF (EF ≤35%). Beta-blockers reduce SCD by preventing ventricular arrhythmias. Class I drugs increase mortality (CAST trial). Amiodarone does not reduce mortality in post-MI HF.

Q138. Colchicine is used in the treatment and prevention of:

A) Dilated cardiomyopathy
B) Acute and recurrent pericarditis (COPE/ICAP trials showed halving of recurrence rate)
C) Cardiac tamponade
D) Constrictive pericarditis

Answer: B - Colchicine inhibits IL-1 and neutrophil migration, reducing pericardial inflammation. The COPE and ICAP trials showed colchicine (0.5 mg BID x 3 months) added to NSAIDs/aspirin halves the rate of recurrent pericarditis.

Q139. Atropine is used in symptomatic bradycardia by:

A) Directly stimulating the SA node
B) Blocking muscarinic receptors, removing vagal inhibition of SA and AV nodes
C) Beta-1 receptor stimulation
D) Inhibiting adenosine

Answer: B - Atropine is a competitive muscarinic (M2) receptor antagonist that blocks vagal tone on the SA and AV nodes, increasing heart rate and AV conduction. Dose: 0.5-1 mg IV (minimum 0.5 mg to avoid paradoxical bradycardia).

Q140. Epinephrine in cardiac arrest (pulseless VT/VF/asystole/PEA) works primarily by:

A) Improving coronary perfusion pressure via alpha-1 vasoconstriction, increasing the chance of defibrillation success
B) Directly defibrillating the heart
C) Activating beta-2 receptors in the lung
D) Blocking vagal tone

Answer: A - In cardiac arrest, epinephrine 1 mg IV every 3-5 minutes works primarily through alpha-1 receptor-mediated peripheral vasoconstriction, increasing aortic diastolic pressure and thus coronary perfusion pressure. This improves perfusion to the heart, enhancing the chance of successful defibrillation.

Q141. Amiodarone's very long half-life (40-55 days) has which clinical implication?

A) Drug can be loaded once and given monthly
B) After stopping, effects persist for months; drug interactions and toxicity risks continue for months after discontinuation
C) No drug interactions since half-life is so long
D) Thyroid effects are temporary

Answer: B - Amiodarone's extremely long and variable half-life (40-55 days) means its effects persist for months after discontinuation. Interactions with warfarin, digoxin, and statins continue long after stopping. Pulmonary toxicity may not resolve quickly.

Q142. In a patient with AF and concurrent HF with reduced EF, the preferred rate control agent is:

A) Verapamil or diltiazem
B) Digoxin or beta-blocker (carvedilol, metoprolol)
C) Flecainide
D) Amiodarone as first-line for rate control

Answer: B - Non-dihydropyridine CCBs (verapamil, diltiazem) are contraindicated in HFrEF due to negative inotropy. Beta-blockers (especially carvedilol, metoprolol succinate) are preferred for rate control in AF + HFrEF. Digoxin can be added if HR remains uncontrolled.

Q143. Eplerenone is preferred over spironolactone in:

A) Severe HF (NYHA IV)
B) Post-MI HF or patients requiring hormonal side effect avoidance (gynecomastia, impotence)
C) Patients with hyperkalemia
D) Patients on ACE inhibitors only

Answer: B - Eplerenone is a selective mineralocorticoid receptor antagonist without anti-androgenic or progesterone receptor activity. It is approved post-MI with EF <40% and signs/symptoms of HF (EPHESUS trial). Preferred when gynecomastia/hormonal effects are concerns.

Q144. The drug approved for reducing the risk of MI in patients with elevated hsCRP but normal LDL (JUPITER trial) is:

A) Niacin
B) Rosuvastatin
C) Ezetimibe
D) Colchicine

Answer: B - The JUPITER trial showed rosuvastatin 20 mg daily in patients with low LDL (<130 mg/dL) but elevated hsCRP (>2 mg/L) significantly reduced cardiovascular events, expanding statin use to primary prevention in this population.

Q145. Ivabradine is indicated in HFrEF when:

A) Rate control in AF is needed
B) Patient is in sinus rhythm with HR ≥70 bpm despite maximum tolerated beta-blocker dose (SHIFT trial)
C) Patient has bradycardia
D) As first-line heart rate control before beta-blockers

Answer: B - Ivabradine is approved for HFrEF (EF ≤35%) in patients in sinus rhythm with resting HR ≥70 bpm despite maximum tolerated beta-blocker. SHIFT trial showed reduced HF hospitalization. NOT effective in AF (sinus node-specific mechanism).

Q146. A patient on amiodarone develops photosensitivity and blue-grey skin discoloration. This is due to:

A) Iodine in the drug causing thyroid-mediated pigmentation
B) Deposition of lipofuscin-amiodarone complexes in skin, enhanced by UV light
C) Allergic reaction
D) Liver disease causing jaundice

Answer: B - Amiodarone causes photosensitivity and, with long-term use, a blue-grey/slate-grey skin discoloration (especially on sun-exposed areas) due to deposition of amiodarone and its metabolites as lipofuscin complexes in dermal macrophages.

Q147. Which of the following prolongs the QTc interval and requires ECG monitoring?

A) Amlodipine
B) Lisinopril
C) Dofetilide
D) Furosemide

Answer: C - Dofetilide is a pure Class III antiarrhythmic (selective IKr blocker) that prolongs QTc. It MUST be initiated in a monitored hospital setting for at least 3 days due to risk of TdP (2-3%). QTc and renal function must be monitored.

Q148. Levosimendan, used in acute HF, works by:

A) Inhibiting PDE3
B) Calcium sensitization (increases myofilament sensitivity to Ca2+ without increasing intracellular Ca2+) and KATP channel opening (vasodilation)
C) Beta-1 stimulation
D) Blocking Na-K-ATPase

Answer: B - Levosimendan (calcium sensitizer) binds troponin C and stabilizes the Ca2+-bound conformation without increasing intracellular Ca2+ (unlike digoxin/dobutamine), improving contractility without arrhythmogenic risk. It also opens KATP channels causing vasodilation.

Q149. Omega-3 fatty acids (icosapentaenoic acid - IPE, as in icosapentaenoic ethyl ester/Vascepa) reduce cardiovascular events in patients with elevated triglycerides through:

A) LDL reduction primarily
B) Reducing TG, anti-inflammatory effects, plaque stabilization, and anti-thrombotic effects (REDUCE-IT trial: 25% RRR in MACE)
C) Increasing HDL primarily
D) Inhibiting platelet COX-1

Answer: B - The REDUCE-IT trial showed icosapentaenoic acid (pure EPA) 4g/day reduced major adverse cardiovascular events (MACE) by 25% relative risk reduction in statin-treated patients with elevated TG (≥150 mg/dL). Mechanisms beyond TG lowering are anti-inflammatory and plaque-stabilizing.

Q150. A 65-year-old male with HFrEF (EF 28%), sinus rhythm at HR 82 bpm on maximum metoprolol succinate, enalapril, furosemide, and spironolactone is still symptomatic with NYHA Class III. The BEST next pharmacological step is:

A) Add digoxin
B) Switch enalapril to sacubitril/valsartan (after 36-hour washout)
C) Add amlodipine
D) Add amiodarone

Answer: B - The PARADIGM-HF trial demonstrated sacubitril/valsartan reduced CV death and HF hospitalization by 20% vs enalapril in symptomatic HFrEF. Current guidelines give a Class I recommendation to switch from ACEi/ARB to ARNI in HFrEF patients who tolerate ACEi/ARB and remain symptomatic. Also consider adding SGLT2 inhibitor (empagliflozin/dapagliflozin) and/or ivabradine if HR remains ≥70 bpm.

SUMMARY TABLE: KEY ADRs & Contraindications

Drug Class	Key ADR	Key Contraindication
Beta-blockers	Bronchospasm, bradycardia, fatigue, masking hypoglycemia	Asthma, advanced heart block, cardiogenic shock
ACE inhibitors	Dry cough (bradykinin), angioedema, hyperkalemia	Pregnancy, bilateral RAS, angioedema history
ARBs	Hyperkalemia, angioedema (rare)	Pregnancy, with ACEi + aliskiren in DM/CKD
CCBs (DHP)	Pedal edema, reflex tachycardia	Avoid nifedipine in STEMI (short-acting)
CCBs (non-DHP)	Bradycardia, constipation, AV block	Systolic HF, advanced heart block
Loop diuretics	Hypokalemia, ototoxicity, hyperuricemia	Anuria
Thiazides	Hypokalemia, hyperglycemia, hyperuricemia, hyponatremia	Gout (relative)
Spironolactone	Hyperkalemia, gynecomastia	CrCl <30, K+ >5.0 mEq/L
Digoxin	Bradycardia, AV block, GI upset, visual changes	WPW, HCM with obstruction, hypokalemia
Amiodarone	Pulmonary toxicity, thyroid dysfunction, corneal deposits, photosensitivity, hepatotoxicity	Thyroid disease (relative)
Statins	Myopathy, rhabdomyolysis, elevated LFTs	Pregnancy, active hepatic disease
Warfarin	Bleeding, skin necrosis (protein C depletion)	Pregnancy, active bleeding,
Heparin (UFH)	HIT, bleeding, osteoporosis	HIT history
DOACs	Bleeding	Mechanical heart valves, severe renal failure (dabigatran)
Nitrates	Hypotension, headache, tolerance	Concomitant PDE5 inhibitors, hypotension
Fibrates	Myopathy (with statins)	Severe renal/hepatic disease

These 150 MCQs cover all key cardiology pharmacology topics for the SPLE Doctor of Pharmacy I examination, including mechanisms, ADRs, contraindications, drug interactions, clinical scenarios, and current evidence-based guidelines.

This is a shared conversation. Sign in to Orris to start your own chat.